197 related articles for article (PubMed ID: 25766918)
1. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.
Gauthé M; Richard-Molard M; Cacheux W; Michel P; Jouve JL; Mitry E; Alberini JL; Lièvre A;
Dig Liver Dis; 2015 Jun; 47(6):443-54. PubMed ID: 25766918
[TBL] [Abstract][Full Text] [Related]
2. [Positron emission tomography (PET) in gastro-intestinal cancer].
Wartski M
Presse Med; 2016 Sep; 45(9):734-41. PubMed ID: 27542763
[TBL] [Abstract][Full Text] [Related]
3. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
Donswijk ML; Hess S; Mulders T; Lam MG
PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
[TBL] [Abstract][Full Text] [Related]
4. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. [Value of [18F]-fluorodeoxyglucose (FDG) positron emission tomography in digestive cancerology].
Montravers F; Kerrou K; Grahek D; Zerbib E; Mabille L; Younsi N; Petegnief Y; De Beco V; Colombet-Lamau C; Talbot JN
Presse Med; 2002 Oct; 31(33):1560-8. PubMed ID: 12422485
[TBL] [Abstract][Full Text] [Related]
7. FDG PET/CT in the management of colorectal and anal cancers.
Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
[TBL] [Abstract][Full Text] [Related]
8. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
9. FDG PET and PET/CT.
Krause BJ; Schwarzenböck S; Souvatzoglou M
Recent Results Cancer Res; 2013; 187():351-69. PubMed ID: 23179888
[TBL] [Abstract][Full Text] [Related]
10. FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity.
Pasha MA; Marcus C; Fakhry C; Kang H; Kiess AP; Subramaniam RM
AJR Am J Roentgenol; 2015 Aug; 205(2):W150-61. PubMed ID: 26001119
[TBL] [Abstract][Full Text] [Related]
11. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
12. Applications of Fluorodeoxyglucose PET/Computed Tomography in the Assessment and Prediction of Radiation Therapy-related Complications.
Houshmand S; Boursi B; Salavati A; Simone CB; Alavi A
PET Clin; 2015 Oct; 10(4):555-71. PubMed ID: 26384600
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
Culverwell AD; Chowdhury FU; Scarsbrook AF
Abdom Imaging; 2012 Dec; 37(6):1021-31. PubMed ID: 22371087
[TBL] [Abstract][Full Text] [Related]
14. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
15. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
[TBL] [Abstract][Full Text] [Related]
16. [PET and digestive cancers].
Talbot JN; Montravers F; Gutman F; Kerrou K; Huchet V; Grahek D; Andre T; Houry S; Touboul E; Rosmorduc O; Poupon R; Ruszniewski P; Rougier P; Grange JD
Presse Med; 2008 Feb; 37(2 Pt 2):e1-e24. PubMed ID: 17951024
[TBL] [Abstract][Full Text] [Related]
17. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
[TBL] [Abstract][Full Text] [Related]
18. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
[TBL] [Abstract][Full Text] [Related]
19. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
